98%
921
2 minutes
20
Diffuse large B-cell lymphoma (DLBCL) with central nervous system (CNS) relapse is associated with a poor prognosis, and treatment becomes particularly challenging in such cases when complicated by polycythemia vera (PV). We report a unique case of CNS-relapsed DLBCL coexisting with PV, successfully treated with autologous stem cell transplantation (ASCT). A 64-year-old man achieved complete remission following R-CHOP therapy for DLBCL but developed isolated CNS relapse one year later. After achieving partial remission with high-dose methotrexate, he was referred for ASCT. On admission, erythrocytosis prompted further evaluation, leading to a diagnosis of JAK2 V617F-positive PV with an allele burden of 37.7%. Following phlebotomy, peripheral blood stem cells were successfully mobilized using reduced-dose G-CSF and plerixafor. ASCT was performed using a conditioning regimen of busulfan and thiotepa. Neutrophil engraftment occurred by day 10 without major adverse events. At 30 months post-ASCT, the patient remains in complete remission, with stable hemoglobin levels, a reduced JAK2 V617F allele burden (~ 12%), and no need for further phlebotomy. This case highlights the feasibility and potential dual therapeutic benefit of thiotepa-based ASCT in patients with coexisting CNS-relapsed DLBCL and PV. To our knowledge, this is the first reported case of ASCT in this clinical context.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1007/s12185-025-04025-w | DOI Listing |
J Pediatr Hematol Oncol
September 2025
Nuclear Medicine, Gujarat Cancer and Research Institute, Ahmedabad, Gujarat, India.
Pediatric pancreatic neuroblastoma is a rare cancer in children, with only limited cases available in the literature. We report a case of a 4-year-old girl diagnosed with high-risk pancreatic neuroblastoma. The girl was treated with induction chemotherapy followed by autologous stem cell transplant and maintenance with 13-cis-retinoic acid.
View Article and Find Full Text PDFClin Transplant
September 2025
Centro De Hematología y Medicina Interna, Clínica Ruiz, Puebla, Mexico.
Expert Opin Drug Deliv
September 2025
Department of Hematology, The First Affiliated Hospital of Ningbo University, Ningbo, PR China.
Introduction: Hematopoietic stem cell transplantation (HSCT) is a promising treatment option for hematological malignancies. Despite its curative potential, it faces clinical challenges, including relapse and graft-versus-host disease (GVHD). Systemic toxicity due to chemotherapy is a significant problem in patients with hematological malignancies.
View Article and Find Full Text PDFZhonghua Bing Li Xue Za Zhi
September 2025
Department of Pathology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China.
To investigate the clinicopathological and genetic characteristics of monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL). The forty-two MEITL cases diagnosed in the Department of Pathology, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China from 2016 to 2022 was retrospectively analyzed. Clinical data were collected, and follow-up was performed.
View Article and Find Full Text PDFJ Immunother Cancer
September 2025
Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China
Background: Patients with acute myeloid leukemia (AML) are often older, which brings challenges of endurance and persistent efficacy of autologous chimeric antigen receptor (CAR)-T cell therapies. Allogenic CAR-natural killer (NK) cell therapies may offer reduced toxicities and enhanced anti-leukemic potential against AML. CD33 CAR-NK cells have been investigated for AML therapy.
View Article and Find Full Text PDF